Abstract
Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B-lymphocytes, T-lymphocytes, or natural killer lymphocytes. An estimated 65,980 new cases of NHL were diagnosed in 2009, and 19,500 patients died of the disease. The median age of individuals with NHL has risen in the past 2 decades, resulting in a patient population that may also have significant comorbid conditions, complicating treatment options. These guidelines reflect significant updates, including the addition of a new guideline for adult T-cell leukemia/lymphoma, modifications to several treatment options for various lymphomas, and the inclusion of new therapies that recently received FDA approval.
Original language | English (US) |
---|---|
Pages (from-to) | 288-334 |
Number of pages | 47 |
Journal | JNCCN Journal of the National Comprehensive Cancer Network |
Volume | 8 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2010 |
Keywords
- Chronic lymphocytic leukemia
- Cutaneous T-cell lymphoma
- Diagnosis
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- Hematopathology
- Immunohistochemistry
- Lymphoma pathology
- Mantle cell lymphoma
- Marginal zone lymphoma
- Mucosa-associated lymphoid tissue lymphoma
- Mycosis fungoides
- NCCN clinical practice guidelines
- Non-Hodgkin's lymphoma
- Peripheral
- Staging evaluation
- Sézary syndrome
- T-cell lymphoma
- Treatment
- Treatment guidelines
ASJC Scopus subject areas
- Oncology